

Bevyn Jarrott

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3534528/publications.pdf>

Version: 2024-02-01

25
papers

632
citations

567281

15
h-index

580821

25
g-index

26
all docs

26
docs citations

26
times ranked

747
citing authors

#	ARTICLE	IF	CITATIONS
1	“LONG COVID” A hypothesis for understanding the biological basis and pharmacological treatment strategy. <i>Pharmacology Research and Perspectives</i> , 2022, 10, e00911.	2.4	69
2	Systems analysis shows that thermodynamic physiological and pharmacological fundamentals drive COVID-19 and response to treatment. <i>Pharmacology Research and Perspectives</i> , 2022, 10, e00922.	2.4	20
3	The interacting physiology of COVID-19 and the renin-angiotensin-aldosterone system: Key agents for treatment. <i>Pharmacology Research and Perspectives</i> , 2022, 10, e00917.	2.4	25
4	Discovery of Aryloxypropylbenzylamines as Voltage-Gated Sodium Channel Na _v 1.2-Subtype-Selective Inhibitors. <i>ChemMedChem</i> , 2019, 14, 570-582.	3.2	3
5	Tacrine: In vivo veritas. <i>Pharmacological Research</i> , 2017, 116, 29-31.	7.1	16
6	Chronic Brain Inflammation: The Neurochemical Basis for Drugs to Reduce Inflammation. <i>Neurochemical Research</i> , 2016, 41, 523-533.	3.3	28
7	Synthesis of six mexiletine derivatives with isoindolines attached as potential antioxidants and their evaluation as cardioprotective agents. <i>MedChemComm</i> , 2015, 6, 634-639.	3.4	2
8	Computational Analysis of Amiloride Analogue Inhibitors of Coxsackie Virus B3 RNA Polymerase. <i>Journal of Proteomics and Bioinformatics</i> , 2014, s9, 004.	0.4	2
9	An improved method to prepare an injectable microemulsion of the galanin-receptor 3 selective antagonist, SNAP 37889, using Kolliphor® HS 15. <i>MethodsX</i> , 2014, 1, 212-216.	1.6	16
10	Synthesis and Preliminary Pharmacological Evaluation of Aryl Dithiolethiones with Cyclooxygenase-2-Selective Inhibitory Activity and Hydrogen Sulfide-Releasing Properties. <i>Australian Journal of Chemistry</i> , 2010, 63, 946.	0.9	30
11	Design and Assessment of a Potent Sodium Channel Blocking Derivative of Mexiletine for Minimizing Experimental Neuropathic Pain in Several Rat Models. <i>Neurochemical Research</i> , 2009, 34, 1816-1823.	3.3	7
12	Synthesis and evaluation of dithiolethiones as novel cyclooxygenase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 459-461.	2.2	10
13	Meloxicam reduces lipopolysaccharide-induced degeneration of dopaminergic neurons in the rat substantia nigra pars compacta. <i>Neuroscience Letters</i> , 2009, 460, 121-125.	2.1	15
14	Pharmacological Characterization Of Bradykinin B1 and B2 Receptors In IMR-90 and INT-407 Human Cell Lines Using A Microphysiometer. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2001, 28, 402-408.	1.9	1
15	Incorporation of sodium channel blocking and free radical scavenging activities into a single drug, AM-36, results in profound inhibition of neuronal apoptosis. <i>British Journal of Pharmacology</i> , 2001, 132, 1691-1698.	5.4	43
16	Chemoenzymatic approaches to the decahydro-as-indacene cores associated with the spinosyn class of insecticide. <i>Journal of the Chemical Society, Perkin Transactions 1</i> , 2000, , 3555-3558.	1.3	12
17	Cardiovascular Effects of Angiotensin-(1-7) in Conscious Spontaneously Hypertensive Rats. <i>Hypertension</i> , 1999, 34, 964-968.	2.7	52
18	Ethanol Consumption by Fawn-Hooded Rats Following Abstinence Effect of Naltrexone and Changes in mu-Opioid Receptor Density. <i>Alcoholism: Clinical and Experimental Research</i> , 1999, 23, 1008-1014.	2.4	59

#	ARTICLE	IF	CITATIONS
19	Development of a novel arylalkylpiperazine compound (AM-36) as a hybrid neuroprotective drug. Drug Development Research, 1999, 46, 261-267.	2.9	15
20	Delayed Treatment With AM-36, a Novel Neuroprotective Agent, Reduces Neuronal Damage After Endothelin-1-Induced Middle Cerebral Artery Occlusion in Conscious Rats. Stroke, 1999, 30, 2704-2712.	2.0	64
21	A comparison of the development of renal hypertension in male and female rats. Clinical Science, 1998, 95, 445-451.	4.3	16
22	Functional GABAA receptors on rat vagal afferent neurones. British Journal of Pharmacology, 1997, 120, 469-475.	5.4	46
23	Adenosine α dopamine receptor interactions in the isolated rat nodose ganglion but not in membranes of dorsal vagal complex. Naunyn-Schmiedeberg's Archives of Pharmacology, 1997, 355, 303-308.	3.0	7
24	Markers of Adenosine Removal in Normotensive and Hypertensive Rat Nervous Tissue. Hypertension, 1996, 28, 1026-1033.	2.7	12
25	Functional dopamine D ₂ receptors on rat vagal afferent neurones. British Journal of Pharmacology, 1995, 114, 1329-1334.	5.4	59